Embryonic Stem Cell Derivatives, and Methods of Making and Using the Same

• US 20090010900A1
• Filed: 06/30/2005
• Published: 01/08/2009
• Est. Priority Date: 07/07/2004
• Status: Abandoned Application

• Current Assignee: Board of Trustees of The University of Illinois
• Original Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Inventors: Cairns, Bruce, Fair, Jeffrey H.
• Application Number:
  US11/596,247
• Publication Number:
  US 20090010900A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: C12N 2501/113 Acidic fibroblast growth factor (aFGF, FGF-1)
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/28 from vascular endothelial cells
• CPC Class Codes: C12N 5/067 Hepatocytes
• CPC Class Codes: C12N 5/0692 Stem cells; Progenitor cells; Precursor cells

Abstract

The presently disclosed subject matter provides embryonic stem (ES) cell derivatives that can be employed in therapeutic methods. Also provided are methods for generating and using the ES cell derivatives.

Claims

16. A method for producing a reagent comprising an in vitro differentiated cell, the method comprising:

(a) providing an embryonic stem (ES) cell or a pre-embryoid body cell; and

(b) differentiating the ES cell or the pre-embryoid body cell in vitro, wherein the differentiating leads to the ES cell or pre-embryoid body cell;

(i) expressing a marker associated with a differentiated cell of interest;

(ii) differentiating into a cell type of interest;

or

(iii) combinations thereof.

17. The method of claim 16, wherein the embryonic stem cell or the pre-embryoid body cell is a mammalian cell.

18. The method of claim 17, wherein the mammalian cell is a human cell.

19. The method of claim 16, wherein the differentiating comprises exposing the embryonic stem cell or the pre-embryoid body cell to a growth factor in an amount and for a time sufficient to provide reduced expression of Oct4 and increased expression of an endodermal marker selected from the group consisting of FoxA2 (HNF-β

3), Gata4, Sox17α

, albumin, and α

-fetoprotein in the embryonic stem cell.

20. The method of claim 19, wherein the growth factor is an acidic fibroblast growth factor (aFGF).

21. A method for generating a putative endoderm precursor cell (PEP) from an embryonic stem cell, the method comprising:

(a) culturing the embryonic stem cell in the absence of feeder cells and LIF; and

(b) exposing the embryonic stem cell to acidic fibroblast growth factor in an amount and for a time sufficient to provide reduced expression of Oct4 and increased expression of an mRNA selected from the group consisting of α

-fetoprotein, Gata4, albumin, FoxA2 (HNF-β

3), and Sox 17α

in the embryonic stem cell, whereby a PEP is generated.

1. A method for treating a disease associated with abnormal or missing function of a tissue, the method comprising:

(a) providing a putative endoderm precursor cell (PEP); and

(b) introducing into a subject in need thereof the PEP, whereby the PEP becomes engrafted in an endoderm-derived tissue of the subject and provides a normal function to or replaces the missing function in the subject, or combinations thereof.

2. The method of claim 1, wherein the subject is a mammal.

3. The method of claim 1, wherein the endoderm-derived tissue is liver.

4. The method of claim 1, wherein the PEP becomes stably engrafted into the endoderm-derived tissue.

5. The method of claim 1, wherein the abnormal or missing function of the tissue results from abnormal or absent function of a cell type of the tissue or abnormal or absent expression of a gene of interest in the tissue.

6. The method of claim 5, wherein the gene of interest is normally expressed in liver cells in the absence of the disease.

7. The method of claim 5, wherein the gene of interest is a Factor IX gene.

8. The method of claim 1, wherein providing a PEP comprises differentiating an embryonic stem cell or a pre-embryoid body cell in vitro to form a PEP.

9. The method of claim 8, wherein the differentiating comprises exposing the embryonic stem cell or the pre-embryoid body cell to a growth factor.

10. The method of claim 9, wherein the growth factor is acidic fibroblast growth factor (aFGF).

11. The method of claim 8, wherein the differentiating results in reduced expression of Oct4 and increased expression of an endodermal marker selected from the group consisting of FoxA2 (HNF-β

3), Gata4, Sox17α

, albumin, and α

-fetoprotein in the in vitro differentiated cell.

12. The method of claim 1, wherein the introducing is into liver parenchyma of the subject.

13. The method of claim 1, wherein the in vitro differentiated cell is allogeneic to the subject.

14. The method of claim 1, wherein the in vitro differentiated cell further comprises a coding sequence that is not normally expressed in the liver of the subject in the absence of disease, but is normally expressed in another tissue or cell type of the subject in the absence of disease.

15. The method of claim 1, further comprising performing a partial hepatectomy on the subject prior to the introducing step.

22. The method of claim 21, wherein the embryonic stem cell is a mammalian embryonic stem cell.

23. The method of claim 22, wherein the embryonic stem cell is a 1 human embryonic stem cell.

24. The method of claim 21, wherein the embryonic stem cells are exposed to acidic fibroblast growth factor in an amount of about 100 ng/ml in a culture medium for about 7 days.

25. The method of claim 21, further comprising purifying the PEP.

26. A putative endoderm precursor cell (PEP), wherein:

(a) the PEP is an in vitro differentiated derivative of an embryonic stem cell; and

(b) expresses a reduced level of Oct4 and an increased level of an mRNA selected from the group consisting of α

-fetoprotein, Gata4, albumin, FoxA2 (HNF-β

3), and Sox 17α

as compared to the embryonic stem cell from which is was derived.

27. The cell of claim 26, wherein the engraftment comprises long term engraftment.

26-1. The cell of claim 25, where the cell is capable of engraftment of an endoderm-derived tissue of a subject when administered into the endoderm-derived tissue.